PT1646389E - Derivados de pirimidina-2,4-diona utilizados como antagonistas do receptor da hormona libertadora de gonadotropina - Google Patents
Derivados de pirimidina-2,4-diona utilizados como antagonistas do receptor da hormona libertadora de gonadotropina Download PDFInfo
- Publication number
- PT1646389E PT1646389E PT04777603T PT04777603T PT1646389E PT 1646389 E PT1646389 E PT 1646389E PT 04777603 T PT04777603 T PT 04777603T PT 04777603 T PT04777603 T PT 04777603T PT 1646389 E PT1646389 E PT 1646389E
- Authority
- PT
- Portugal
- Prior art keywords
- sub
- receptor antagonists
- gonadotropin
- releasing hormone
- pyrimidine
- Prior art date
Links
- 229940127445 Gonadotropin Releasing Hormone Receptor Antagonists Drugs 0.000 title 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 1
- 102000008238 LHRH Receptors Human genes 0.000 abstract 1
- 108010021290 LHRH Receptors Proteins 0.000 abstract 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48543403P | 2003-07-07 | 2003-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1646389E true PT1646389E (pt) | 2008-12-19 |
Family
ID=34079121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04777603T PT1646389E (pt) | 2003-07-07 | 2004-07-06 | Derivados de pirimidina-2,4-diona utilizados como antagonistas do receptor da hormona libertadora de gonadotropina |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7056927B2 (https=) |
| EP (1) | EP1646389B1 (https=) |
| JP (2) | JP4722844B2 (https=) |
| KR (1) | KR101139148B1 (https=) |
| CN (1) | CN100424078C (https=) |
| AT (1) | ATE407679T1 (https=) |
| AU (1) | AU2004257639B2 (https=) |
| BR (1) | BRPI0412314B8 (https=) |
| CA (1) | CA2531508C (https=) |
| CY (1) | CY1108656T1 (https=) |
| DE (1) | DE602004016516D1 (https=) |
| DK (1) | DK1646389T3 (https=) |
| EA (1) | EA010370B1 (https=) |
| ES (1) | ES2314448T3 (https=) |
| HR (1) | HRP20080646T3 (https=) |
| IL (1) | IL172833A (https=) |
| MX (1) | MXPA06000297A (https=) |
| NO (1) | NO334897B1 (https=) |
| NZ (1) | NZ544747A (https=) |
| PL (1) | PL1646389T3 (https=) |
| PT (1) | PT1646389E (https=) |
| SI (1) | SI1646389T1 (https=) |
| WO (1) | WO2005007165A1 (https=) |
| ZA (1) | ZA200600475B (https=) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001055119A2 (en) * | 2000-01-25 | 2001-08-02 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| ES2387495T3 (es) * | 2003-07-07 | 2012-09-25 | Neurocrine Biosciences, Inc. | Arilpirimidinas útiles en el tratamiento de trastornos relacionados con las hormonas sexuales, tales como endometriosis, cáncer de próstata y similares |
| AU2004257639B2 (en) * | 2003-07-07 | 2011-01-06 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| DE602004020638D1 (de) * | 2003-07-07 | 2009-05-28 | Neurocrine Biosciences Inc | Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten |
| UA85871C2 (uk) * | 2004-03-15 | 2009-03-10 | Такеда Фармасьютікал Компані Лімітед | Інгібітори дипептидилпептидази |
| CL2008000986A1 (es) | 2007-04-06 | 2008-10-17 | Neurocrine Biosciences Inc | COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV |
| EP2155194B1 (en) | 2007-04-06 | 2015-01-21 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| MX2010003371A (es) | 2007-09-28 | 2010-05-05 | Intrexon Corp | Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos. |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| JP5757956B2 (ja) * | 2009-11-20 | 2015-08-05 | エスケー ケミカルス シーオー．， エルティーディー．Ｓｋ Ｃｈｅｍｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | ゴナドトロピン放出ホルモン受容体拮抗剤、その製造方法及びそれを含む医薬組成物 |
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| EP2881391A1 (en) | 2013-12-05 | 2015-06-10 | Bayer Pharma Aktiengesellschaft | Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof |
| US10821152B2 (en) | 2014-08-26 | 2020-11-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| US20190321363A1 (en) * | 2016-06-20 | 2019-10-24 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| UA127283C2 (uk) | 2016-07-21 | 2023-07-12 | Обсева С.А. | Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню |
| KR102458763B1 (ko) | 2016-08-23 | 2022-10-26 | 스완 아날라이티쉐 인스트루멘테 아크티엔게젤샤프트 | 액체의 전기 탈이온화 장치 및 방법 |
| TWI778979B (zh) | 2016-09-30 | 2022-10-01 | 瑞士商麥歐文科學有限公司 | 治療女性不孕症之方法 |
| CN110248661A (zh) | 2016-09-30 | 2019-09-17 | 梦欧文科学有限责任公司 | 前列腺癌的治疗 |
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| WO2018111990A1 (en) * | 2016-12-14 | 2018-06-21 | Purdue Research Foundation | Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof |
| AU2018251951B2 (en) | 2017-04-12 | 2020-09-03 | Sandoz Ag | Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist |
| EP3388421B1 (en) | 2017-04-13 | 2019-12-04 | Sandoz AG | Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist |
| PT3388422T (pt) | 2017-04-13 | 2020-02-18 | Sandoz Ag | Dispersão sólida amorfa de um antagonista dos recetores de hormonas libertadoras de gonadotrofina disponível por via oral |
| WO2018198086A1 (en) * | 2017-04-28 | 2018-11-01 | Lupin Limited | Process for the preparation of elagolix and pharmaceutically acceptable salts thereof |
| SG11201911598WA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| WO2018224063A2 (en) * | 2017-06-08 | 2018-12-13 | Zentiva, K.S. | Solid forms of elagolix |
| US20190054088A1 (en) * | 2017-08-18 | 2019-02-21 | Abbvie Inc. | Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis |
| TW201912157A (zh) | 2017-08-18 | 2019-04-01 | 美商艾伯維有限公司 | 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物 |
| CN111698992A (zh) * | 2017-08-18 | 2020-09-22 | 艾伯维公司 | 用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物 |
| CN107935863A (zh) * | 2017-11-30 | 2018-04-20 | 厦门海乐景生化有限公司 | Elagolix的关键原料化合物C的合成方法 |
| CN110938037A (zh) * | 2018-09-21 | 2020-03-31 | 苏州鹏旭医药科技有限公司 | 一种依拉戈利钠盐药物中间体的制备方法 |
| JP7200261B2 (ja) * | 2017-12-05 | 2023-01-06 | スージョウ ポンシュー ファーマテック カンパニー リミテッド | エラゴリクスを作製するプロセス |
| EP3724167A1 (en) | 2017-12-11 | 2020-10-21 | Synthon B.V. | Process for preparing elagolix |
| CN109970663B (zh) * | 2017-12-27 | 2023-04-11 | 上海科胜药物研发有限公司 | 一种制备噁拉戈利中间体的方法 |
| CN108129400B (zh) * | 2017-12-29 | 2021-10-15 | 安帝康（无锡）生物科技有限公司 | 氘代噁拉戈利衍生物及其用途 |
| AU2018419533A1 (en) | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| CN110669013A (zh) * | 2018-07-03 | 2020-01-10 | 江苏海悦康医药科技有限公司 | 一种噁拉戈利中间体的制备方法 |
| BR112021000973A2 (pt) * | 2018-07-23 | 2021-04-20 | Abbvie Inc. | composições e processos de sódio de elagolix |
| EP3829584A4 (en) * | 2018-08-01 | 2022-06-08 | Abbvie Inc. | DOSAGE SCHEDULES FOR ELAGOLIX |
| EP3572406A1 (en) | 2018-10-17 | 2019-11-27 | Sandoz Ag | Acid addition salt of elagolix and related compounds |
| CA3117092A1 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| SG11202104053TA (en) | 2018-11-07 | 2021-05-28 | ObsEva SA | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN109293634A (zh) * | 2018-12-04 | 2019-02-01 | 中国药科大学 | 恶拉戈利杂质的制备方法 |
| CN109651171A (zh) * | 2019-01-13 | 2019-04-19 | 苏州鹏旭医药科技有限公司 | 依拉戈利及其钠盐的中间体及其盐的制备方法和应用 |
| PH12021551685A1 (en) | 2019-01-15 | 2022-05-16 | Lupin Inc | Deuterated elagolix-like compositions and methods |
| CN109761913A (zh) * | 2019-02-16 | 2019-05-17 | 安徽华胜医药科技有限公司 | 一种有机金属钯催化合成elagolix中间体的方法 |
| CN109651265A (zh) * | 2019-02-16 | 2019-04-19 | 安徽诺全药业有限公司 | 一种Elagolix的制备方法 |
| CN109810065B (zh) * | 2019-02-16 | 2022-07-15 | 安徽华胜医药科技有限公司 | 一种恶拉戈利的合成方法 |
| CN110041232A (zh) * | 2019-04-10 | 2019-07-23 | 丽珠集团新北江制药股份有限公司 | 一种制备GnRHR药物关键中间体化合物的方法 |
| CN109956906B (zh) * | 2019-04-19 | 2021-01-29 | 奥锐特药业股份有限公司 | 一种噁拉戈利关键中间体的制备方法 |
| US20220242831A1 (en) * | 2019-05-24 | 2022-08-04 | Dr. Reddy's Laboratories Limited | Improved process for the preparation of elagolix and its intermediates |
| CN110204498B (zh) * | 2019-06-14 | 2020-11-27 | 奥锐特药业股份有限公司 | 一种高效合成噁拉戈利中间体的方法 |
| CN110372608A (zh) * | 2019-07-09 | 2019-10-25 | 丽珠集团新北江制药股份有限公司 | 一种促性腺激素释放激素拮抗剂的制备方法 |
| ES2802815B2 (es) * | 2019-07-12 | 2022-03-14 | Moehs Iberica Sl | Sal clorhidrato de 3-[2(r)-amino-2-feniletil]-5-(2-fluoro-3-metoxifenil)-1-[2-fluoro-6-(trifluorometil)bencil]-6-metil-1h-pirimidin-2,4(1h,3h)-diona (i) en forma solida, procedimiento para su preparacion y uso de la misma en la sintesis de elagolix |
| CN110372609B (zh) * | 2019-07-25 | 2021-04-09 | 奥锐特药业股份有限公司 | 一种噁拉戈利钠盐的纯化方法 |
| CN112672998B (zh) * | 2019-07-31 | 2022-06-21 | 深圳仁泰医药科技有限公司 | 恶拉戈利与乙胺嘧啶的共晶型a及其制备方法和用途 |
| AU2020325721A1 (en) | 2019-08-08 | 2022-03-03 | ObsEva S.A. | GnRH antagonists for the treatment of estrogen-dependent disorders |
| AU2020325655B2 (en) | 2019-08-08 | 2025-09-11 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of estrogen-dependent disorders |
| US20220323410A1 (en) | 2019-09-03 | 2022-10-13 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| IT201900015458A1 (it) * | 2019-09-03 | 2021-03-03 | Ind Chimica Srl | Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo |
| BR112022003622A2 (pt) * | 2019-09-03 | 2022-05-24 | Ind Chimica Srl | Processo para a síntese do sal de sódio do ácido 4-[[(1r)-2-[5-(2-flúor-3-metoxifenil)-3-[[2-flúor-6-(trifluormetil)-fenil]metil]-3,6-diidro-4-metil-2,6-dioxo-1(2h)-pirimidinila]-1-feniletil]amino]-butanóico (sal de sódio de elagolix) e intermediários do referido processo |
| IT202000001390A1 (it) * | 2020-01-24 | 2021-07-24 | Ind Chimica Srl | Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo |
| TWI755055B (zh) * | 2019-09-18 | 2022-02-11 | 台灣神隆股份有限公司 | 用於製備惡拉戈利鈉及其中間體的方法 |
| WO2021064561A1 (en) * | 2019-10-03 | 2021-04-08 | Neuland Laboratories Limited | An improved process for the preparation of elagolix sodium |
| CN112694445B (zh) * | 2019-10-22 | 2023-07-28 | 成都倍特药业股份有限公司 | 一种噁拉戈利钠中间体的纯化方法 |
| ES2822398B2 (es) | 2019-10-30 | 2022-03-02 | Moehs Iberica Sl | 3-((R)-2-(Amino-2-feniletil)-1-(2-fluoro-6-trifluorometilbencil)-5-yodo-6-metil-1H-pirimidin-2,4-diona o una sal de la misma, procedimiento para su preparación y su uso en la síntesis de elagolix |
| WO2021130776A1 (en) * | 2019-12-27 | 2021-07-01 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of 4-({(1 r)-2-[5-(2-fluoro-3methoxyphenyl)-3-{[2-fluoro-6-(trifluoro methyl) phenyl]methyl}-4-methyl-2,6-dioxo-3,6dihydropyrimidin-1(2 h)-yl]-1-phenylethyl}amino)butanoic acid or its pharmaceutically acceptable salts |
| CN113125575B (zh) * | 2019-12-31 | 2023-04-18 | 济南尚博生物科技有限公司 | 一种1-(2-氟-6-(三氟甲基)苄基)-6-甲基嘧啶-二酮的定量分析方法 |
| CN111116490A (zh) * | 2020-01-15 | 2020-05-08 | 奥锐特药业股份有限公司 | 一种噁拉戈利中间体水杨酸盐的制备与纯化方法 |
| WO2021160597A1 (en) | 2020-02-10 | 2021-08-19 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
| WO2021177999A1 (en) * | 2020-03-05 | 2021-09-10 | Abbvie Inc. | Methods of administering elagolix |
| WO2021180862A1 (en) | 2020-03-12 | 2021-09-16 | Synthon B.V. | Pharmaceutical compositions comprising elagolix sodium |
| CN111333548B (zh) * | 2020-04-10 | 2022-04-26 | 江苏海悦康医药科技有限公司 | 1-(2-氟-6-(三氟甲基)苄基)脲的制备方法 |
| CN113527213B (zh) * | 2020-04-20 | 2023-01-03 | 上海英诺富成生物科技有限公司 | 促性激素释放激素受体拮抗剂及其用途 |
| CN113683572A (zh) * | 2020-05-18 | 2021-11-23 | 陈晓雯 | 噁拉戈利的中间体及其制备方法和应用 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| CN113880773A (zh) * | 2020-07-02 | 2022-01-04 | 南京药石科技股份有限公司 | 一种噁拉戈利中间体的制备方法 |
| CN112457258A (zh) * | 2020-11-26 | 2021-03-09 | 诚达药业股份有限公司 | 一种噁拉戈利钠及其中间体的制备方法 |
| EP4284374A1 (en) | 2021-01-29 | 2023-12-06 | Abbvie Inc. | Methods of administrating elagolix |
| KR102656087B1 (ko) | 2024-01-12 | 2024-04-09 | 주식회사 씨엠지 | Led 소자의 에폭시 수지 코팅층 형성 방법 |
| WO2026018221A1 (en) | 2024-07-18 | 2026-01-22 | ReproNovo SA | Crystalline compositions for improving embryo implantation and methods of using the same |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5844896A (en) | 1995-06-01 | 1996-12-18 | Takeda Chemical Industries Ltd. | Tricyclic diazepines useful as gnrh receptor antagonists |
| CN1200114A (zh) | 1995-10-19 | 1998-11-25 | 武田药品工业株式会社 | 作为gnrh拮抗剂的喹啉衍生物 |
| CN1063446C (zh) | 1995-10-19 | 2001-03-21 | 武田药品工业株式会社 | 作为促性腺激素释放激素拮抗剂的噻吩并吡啶衍生物 |
| WO1997021435A1 (en) | 1995-12-14 | 1997-06-19 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| CN1208412A (zh) * | 1995-12-14 | 1999-02-17 | 麦克公司 | 促性腺激素释放激素拮抗剂 |
| SK77598A3 (en) | 1995-12-14 | 1999-01-11 | Merck & Co Inc | Nonpeptide derivatives, pharmaceutical composition containing them and their use |
| JP3092946B2 (ja) | 1995-12-14 | 2000-09-25 | メルク エンド カンパニー インコーポレーテッド | ゴナドトロピン放出ホルモン拮抗剤 |
| EP0986385A4 (en) | 1997-06-05 | 2001-05-16 | Merck & Co Inc | GONADORELIN ANTAGONISTS |
| AU7806998A (en) | 1997-06-05 | 1998-12-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| WO1998055479A1 (en) | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| AU729752B2 (en) | 1997-06-05 | 2001-02-08 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6313301B1 (en) | 1997-08-13 | 2001-11-06 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives, their intermediates and production thereof |
| CA2372044A1 (en) | 1999-05-14 | 2000-11-23 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| US20020065309A1 (en) | 1999-08-04 | 2002-05-30 | Ge Peng | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists |
| MXPA02003614A (es) | 1999-10-15 | 2002-10-23 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos.. |
| WO2001055119A2 (en) * | 2000-01-25 | 2001-08-02 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| SE0100566D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| WO2003011870A1 (en) | 2001-08-02 | 2003-02-13 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists |
| US6939883B2 (en) | 2001-08-02 | 2005-09-06 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| JP2005500352A (ja) | 2001-08-02 | 2005-01-06 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | ゴナドトロピン放出ホルモンレセプター（ＧｎＲＨ）アンタゴニストとしての１，２，４−トリアジン−３，５−ジオン |
| EP1411941A2 (en) | 2001-08-02 | 2004-04-28 | Neurocrine Biosciences, Inc. | Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists |
| AU2002324586B2 (en) | 2001-08-02 | 2008-04-24 | Neurocrine Biosciences, Inc. | 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| DE602004020638D1 (de) | 2003-07-07 | 2009-05-28 | Neurocrine Biosciences Inc | Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten |
| AU2004257639B2 (en) * | 2003-07-07 | 2011-01-06 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| ES2387495T3 (es) | 2003-07-07 | 2012-09-25 | Neurocrine Biosciences, Inc. | Arilpirimidinas útiles en el tratamiento de trastornos relacionados con las hormonas sexuales, tales como endometriosis, cáncer de próstata y similares |
-
2004
- 2004-07-06 AU AU2004257639A patent/AU2004257639B2/en not_active Expired
- 2004-07-06 JP JP2006518842A patent/JP4722844B2/ja not_active Expired - Lifetime
- 2004-07-06 AT AT04777603T patent/ATE407679T1/de active
- 2004-07-06 ES ES04777603T patent/ES2314448T3/es not_active Expired - Lifetime
- 2004-07-06 DK DK04777603T patent/DK1646389T3/da active
- 2004-07-06 EA EA200600190A patent/EA010370B1/ru unknown
- 2004-07-06 PT PT04777603T patent/PT1646389E/pt unknown
- 2004-07-06 SI SI200430940T patent/SI1646389T1/sl unknown
- 2004-07-06 CN CNB2004800195023A patent/CN100424078C/zh not_active Expired - Lifetime
- 2004-07-06 KR KR1020067000436A patent/KR101139148B1/ko not_active Expired - Lifetime
- 2004-07-06 US US10/885,491 patent/US7056927B2/en not_active Expired - Lifetime
- 2004-07-06 ZA ZA200600475A patent/ZA200600475B/xx unknown
- 2004-07-06 PL PL04777603T patent/PL1646389T3/pl unknown
- 2004-07-06 WO PCT/US2004/021593 patent/WO2005007165A1/en not_active Ceased
- 2004-07-06 HR HR20080646T patent/HRP20080646T3/xx unknown
- 2004-07-06 BR BRPI0412314A patent/BRPI0412314B8/pt not_active IP Right Cessation
- 2004-07-06 CA CA2531508A patent/CA2531508C/en not_active Expired - Fee Related
- 2004-07-06 NZ NZ544747A patent/NZ544747A/en not_active IP Right Cessation
- 2004-07-06 EP EP04777603A patent/EP1646389B1/en not_active Expired - Lifetime
- 2004-07-06 MX MXPA06000297A patent/MXPA06000297A/es active IP Right Grant
- 2004-07-06 DE DE602004016516T patent/DE602004016516D1/de not_active Expired - Lifetime
-
2005
- 2005-10-14 US US11/251,085 patent/US7176211B2/en not_active Expired - Lifetime
- 2005-12-26 IL IL172833A patent/IL172833A/en active Protection Beyond IP Right Term
- 2005-12-30 NO NO20056251A patent/NO334897B1/no unknown
-
2007
- 2007-01-25 US US11/627,204 patent/US7419983B2/en active Active
-
2008
- 2008-12-09 CY CY20081101424T patent/CY1108656T1/el unknown
-
2010
- 2010-11-29 JP JP2010265830A patent/JP5226760B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200600475B (en) | Pyrimidine-2,4-dione derivatives as gonadotripin-releasing hormone receptor antagonists | |
| IL172834A0 (en) | Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same | |
| WO2001055119A3 (en) | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | |
| WO2003011293A3 (en) | Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists | |
| SI1678166T1 (sl) | Inhibitorji proteinske kinaze | |
| DE60022769D1 (de) | Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen | |
| IL142893A0 (en) | Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same | |
| HUP0301892A2 (hu) | Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| ATE557007T1 (de) | Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen | |
| ATE316078T1 (de) | 1,3,5-triazine-2,4,6-trione, herstellung und anwendungen als antagonisten der gonadotropin- freisetzenden hormonrezeptoren | |
| IL158806A0 (en) | Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists | |
| AU2001261850A1 (en) | Crf receptor antagonists and methods relating thereto | |
| ATE398131T1 (de) | Kondensierte camptothecine als antitumormittel | |
| AU2001263329A1 (en) | Crf receptor antagonists and methods relating thereto | |
| PL1684763T3 (pl) | 6-arylo-7-halogeno-imidazo[1,2-a]pirymidyny jako środki przeciwnowotworowe |